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Abstract
RUNX1 encodes a DNA binding subunit of the core-binding transcription factors and is frequently mutated in acute
leukemia, therapy-related leukemia, myelodysplastic syndrome, and chronic myelomonocytic leukemia. Mutations in RUNX1
are thought to confer upon hematopoietic stem cells (HSCs) a pre-leukemic state, but the fundamental properties of Runx1
deficient pre-leukemic HSCs are not well defined. Here we show that Runx1 deficiency decreases both apoptosis and
proliferation, but only minimally impacts the frequency of long term repopulating HSCs (LT-HSCs). It has been variously
reported that Runx1 loss increases LT-HSC numbers, decreases LT-HSC numbers, or causes age-related HSC exhaustion. We
attempt to resolve these discrepancies by showing that Runx1 deficiency alters the expression of several key HSC markers,
and that the number of functional LT-HSCs varies depending on the criteria used to score them. Finally, we identify genes
and pathways, including the cell cycle and p53 pathways that are dysregulated in Runx1 deficient HSCs.
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Introduction
One of the most commonly mutated genes in leukemia is
RUNX1, which encodes a DNA-binding subunit of the heterodi-
meric core-binding factors. Chromosomal translocations involving
RUNX1 are found in multiple hematopoietic malignancies
including acute myelogenous leukemia (AML), acute lymphocytic
leukemia (ALL), and therapy-related AML and myelodysplastic
syndrome (MDS). For example, the t(8;21)(q22;q22) which fuses
Runx1 (or AML1) to the ETO protein (encoded by RUNX1T1)i s
found in 5–12% of de novo AML. Mono- or biallelic deletions,
missense, nonsense, and frameshift mutations in RUNX1 are also
found in patients with de novo AML, MDS, chronic myelomono-
cytic leukemia, and in therapy-related MDS and AML
[1,2,3,4,5,6,7]. Missense mutations are most commonly found in
the DNA binding Runt domain, with other mutations scattered
throughout the coding sequences. RUNX1 mutations are found in
approximately 5–6% of de novo AML patients, but the mutation
frequency is reportedly quite high in certain leukemia subtypes [7].
For example, a recent analysis of 449 de novo AML patients with
normal karyotype or non complex chromosomal imbalances
identified RUNX1 mutations in 32.7% of cases, including 65%
of the least differentiated French-American-British (FAB) subtype
(AML M0) [6]. The mechanism by which Runx1 loss contributes
to AML or MDS is not entirely clear, nor is it understood why de
novo AML associated with biallelic loss of function RUNX1
mutations confers a considerably worse prognosis than, for
example, de novo AML with the (8;21) translocation [6,8,9].
Chromosomal translocations and mutations in RUNX1 can be
initiating events that occur in HSCs, after which leukemias
clonally evolve through the acquisition of secondary mutations
[6,10,11]. A thorough characterization of the cell-autonomous
impact of Runx1 loss on HSCs and progenitors is therefore
essential for understanding the pre-leukemic state conferred by
RUNX1 mutations, and for identifying potential therapeutic targets
for eliminating leukemic or preleukemic HSCs. Germline deletion
of Runx1 in mice is lethal and blocks blood cell formation [12,13].
However, if Runx1 function is lost or compromised after HSCs in
the fetus have formed, lineage negative Sca1
+ c-Kit
+ (LSK) cells
and committed myeloid progenitors are not lost, but instead
expand several fold in the bone marrow [14,15,16,17,18]. Mice
with Runx1 deficient HSCs do not spontaneously develop
leukemia, but are sensitized to leukemia caused by experimentally
induced secondary mutations [18]. It is not entirely clear which
specific properties of Runx1 deficient HSCs contribute to the pre-
leukemic state. Presumably, though, for leukemia to evolve, Runx1
deficient HSCs must self-renew and persist in the bone marrow, as
shown to be the case for HSCs expressing the t(12;21) product,
TEL-AML1 [10].
Here we analyzed the cell-autonomous properties of Runx1
deficient HSCs. Deletion of Runx1 expanded the number of LSK
cells, consistent with all previous reports [15,16,17,18,19]. All
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cycle delay and decreased apoptosis. The number of functional
Runx1 deficient LT-HSCs in the young adult bone marrow was
either moderately decreased or unchanged, depending on
whether contribution to peripheral blood or bone marrow was
assessed. Runx1 deficiency influenced the expression of several
LT-HSC markers, which may explain some of the contradictory
reports in the literature on the effect of Runx1 deletion on
phenotypic LT-HSCs [18,20]. Finally, we report on the genes
deregulated upon Runx1 deletion, and the potential pathways
that are affected.
Methods
Mice
Mice were housed in microisolator cages in a pathogen-free
animal facility and were treated according to Dartmouth’s and the
University of Pennsylvania’s Animal Resources Center and
IACUC protocols. The colonies of Runx1
f/f; Mx1-Cre and
Runx1
f/f;Vav1-Cre mice were generated and maintained as
described previously [14,15]. Genotyping for the Tg(Mx1-Cre)
allele was performed by polymerase chain reaction (PCR) using
1 mlo f1 0mM internal control forward primer (oIMR0042, 59
CTA GGC CAC AGA ATT GAA AGA TCT 39), 1 mlo f1 0mM
internal control reverse primer (oIMR0043, 59 GTA GGT GGA
AAT TCT AGC ATC ATC C 39), 1 mlo f1 0mM forward primer
(oIMR1084, 59 GCG GTC TGG CAG TAA AAA CTA TC 39),
1 mlo f1 0mM reverse primer (oIMR1085, 59 GTG AAA CAG
CAT TGC TGT CAC TT 39). Genotyping for the Runx1
f allele
(Runx1
tm3Spe), Tg(Vav1-Cre) [21], and evaluation of excision were
described previously [14,15].
Transplant studies
F1 progeny of either 129S1/SvImJ (Ly5.2) females crossed to
B6.SJL-Ptprc
a Pepc
b/BoyJ (Ly5.1) males (JAX, Bar Harbor, ME), or
C57BL6/J (Ly5.2) females crossed to B6.SJL-Ptprc
a Pepc
b/BoyJ
males were used as recipients for Runx1
f/f;Mx1-Cre, Runx1
f/f;Vav1-
Cre, and Runx1
f/f cells. All donor cells were Ly5.2 (CD45.2
+). Bone
marrow chimeras were established by injecting donor fetal or bone
marrow cells along with 2610
5 B6.SJL (carrier CD45.1/Ly5.1)
marrow cells into lethally-irradiated (split dose 900–1200 cGy
3 hours apart) recipients. Engraftment was scored as $1% donor
derived cells.
Serial transplants were initiated by injection of different doses of
donor bone marrow cells into irradiated B6.SJL-Ptprc
a Pepc
b/BoyJ
recipients, without competitors. Reconstitution was assessed two
months later and 2610
6 bone marrow cells from each primary
recipient were transplanted into four secondary B6.SJL-Ptprc
a
Pepc
b/BoyJ recipients. 2610
6 bone marrow cells from each
secondary recipient were transplanted into one or two tertiary
recipients, and from each reconstituted tertiary recipient into a
fourth recipient.
Induction of Tg(Mx1-Cre) and deletion of Runx1
f
Stable donor (Runx1
f/f; Mx1-Cre; or Runx1
f/f) reconstitution of
recipient hematopoiesis was confirmed beginning at one month
post transplant by multicolor flow cytometry. Recipient mice each
received 3 intraperitoneal injections of pIpC (GE Healthcare,
Piscataway NJ) [weight of mouse (g)610 + 50] = ml of 1 mg/ml
pIpC]. Deletion of Runx1
f at a gross level was determined by PCR
of marrow or peripheral blood cells [15] and clonally by PCR of
individual colonies derived from CFU-C cultures. The latter
indicated that deletions were .99% efficient (not shown).
Cell purification and flow cytometry
Flow cytometry analyses were performed with a FACSCalibur,
FACSAria, or LSRII (BD Bioscience, San Jose CA) equipped with
CellQuest Pro or FACS Diva acquisition software. Subsequent
data analyses were carried out using Flowjo (Treestar Inc, Ashland
OR). Lineage depletion of bone marrow was achieved using the
MACS Lineage Cell Depletion Kit, MidiMACS LS Separation
units, and the QuadroMACS Multistand (Miltenyi) according to
the manufacturer’s instructions. In some cases erythrocytes were
lysed in an RBC Lysis Buffer (eBioscience, San Diego, CA) prior to
lineage depletion. A Cellometer (Nexcelom Bioscience, Lawrence
MA) was used to count nucleated cells. The following monoclonal
antibodies (BD Bioscience and/or eBioscience, San Diego CA)
were used for staining: FITC/PE-Cy7-Sca1 (E13-161.7, D7),
APC/APC-Cy7-cKit (2B8), PE/PE-Cy5-CD135 (A2F10), PE-
Cy5/APC-CD45.1 (A20), FITC/APC-CD45.2 (104), FITC/PE-
CD48 (BCM1), CD34 (RAM34), Mac1 (M1/70), Gr1 (RB6-8C5),
CD3e (17A2), B220 RA3-6B2), Ter119 (TER119), and eFluor 450
or PE-Cy5 Streptavidin. Biotin-CD150 (TC15 12F12.2) was from
BioLegend (San Diego CA). Dead cells were stained with
Propidium Iodide (PI) (Sigma, St. Louis MO), 7-AAD, or
ToPro-3 (Molecular Probes/Invitrogen, Carlsbad CA).
Cell cycle analyses
HSCs were sorted into 100% fetal bovine serum (FBS) at 4uC
using a FACSAria cell sorter. Sorted cells were centrifuged for 5
minutes at 300 x g, the supernatant removed, and pelleted cells
resuspended in 1x HBSS containing 1 g/L Glucose, 20 mM
HEPES, and 50 mg/ml Verapamil (Molecular Probes/Invitrogen).
Hoechst 33342 (Molecular Probes/Invitrogen) was added to
10 mg/ml, and cells were incubated at 37uC for 45 minutes.
Pyronin Y (Sigma) was added to 1 mg/ml and cells incubated for a
further 15 minutes at 37uC. Cells were washed 1X, and
immediately analyzed with the FACSAria.
Mice received BrdU intraperitoneally (1 mg/6 g) followed by
administration in drinking water (1 mg/mL) for 3 days. Bone
marrow cells were stained and analyzed according to the
manufacturer’s instructions (BD Bioscience).
Gene expression analyses
Cell populations were sorted under sterile conditions at 4uC
directly into an RNA lysis buffer, RLT containing b-mercapto-
ethanol (Qiagen, Valencia CA) and lysed by incubation at 42uC
for 1 hour followed by 1 minute of vortexing. Total RNA was
DNaseI-treated on Rneasy columns, and purified according to the
manufacturer’s instructions (Qiagen) except that the RNase-free
water used to elute total RNA was heated to 70uC before applying
to the columns. Total RNA quantity and integrity were verified
using an Agilent Bioanalyzer and Pico kit (Agilent Technologies,
Santa Clara CA). First and second round cDNA synthesis, and the
first amplification reaction, was performed using the RiboAmp Kit
(Arcturus, Foster City CA). 450 ng of cDNA was then used as
template for a second in vitro transcription in which biotin-labeled
aRNA was generated with the BioArray High Yield RNA
Transcript labeling kit (T7) (Enzo Life Sciences, Plymouth
Meeting PA) according to the manufacturer’s instructions.
Biotinylated aRNA was submitted to the Shared Resource
Microarray Facility at Dartmouth Medical School for fragmenta-
tion and hybridization to Affymetrix Mouse 430 2.0 GeneChip
arrays (Affymetrix, Santa Clara CA). Affymetrix CEL files were
uploaded using the Microsoft Excel Add-in BRB Array Tools
v3.7.0 and data normalized with the Robust Multichip Average
(RMA) algorithm. A class comparison was performed using the
random variance model, with a significance-threshold of 0.005 to
Effects of Runx1 Loss on Hematopoietic Stem Cells
PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e28430identify differentially expressed probesets. Data were filtered to
exclude any probeset having a mean fold change of less than 1.5
between classes, and non-annotated probesets were eliminated
from further analyses. Microarray data were analyzed by gene set
enrichment analysis (GSEA) [22] according to the online user
guide. Venn diagrams were generated using VENNY [23].
RNA for qRT-PCR was purified by miRNeasy Mini Kit
(Qiagen), and total RNA reverse transcribed (Applied Biosystems,
Carlsbad CA). Reaction mixtures for quantitative PCR contained
5 nM of template DNA and 50 mM of primer DNA in 50 mM
NaCl and 1 mM Mg
++. A three step PCR was performed for 35
cycles. Denaturation was at 94uC for 20 seconds, annealing at
55uC for 20 seconds, and extension at 72uC for 30 seconds.
Primers and probes are listed in Table 1.
Administration of 5-fluorouracil
Mice were injected 5-fluorouracil (150 mg/kg) (Sigma) on days
0, 7, and 14, and both blood and bone marrow analyzed by flow
cytometry.
Results
Runx1 regulates LSK pool size by a cell autonomous
mechanism
We determined if the expansion of LSK cells that occurs upon
conditional deletion of Runx1 in adult bone marrow reflects a true
cell-autonomous role of Runx1 in regulating LSK pool size. We
transplanted total bone marrow from Runx1
f/f; Mx1-Cre or Runx1
f/f
donor mice (Ly5.2) together with wild type competitor (Ly5.1)
bone marrow into lethally irradiated congenic recipients (Ly5.1/
5.2) (Figure 1A). After confirming hematopoietic reconstitution, we
deleted Runx1 and analyzed Ly5.2
+ donor-derived cells at 5 weeks
post deletion. Consistent with all previous reports [15,16,18,19,20]
we observed an expansion of Sca-1
+ c-kit
+ cells within the Lin
-
population (Figure 1B,C). This expansion involved both LSK Flt3
-
cells (LSKF
-), which include all long term and short term
repopulating HSCs (LT-HSCs and ST-HSCs), and LSKF
+ cells
which consist of early multipotent progenitors (MPPs) and
lymphoid-primed MPPs (LMPPs) (Figure 1B,D) [24,25]. The
increase in LSK cells was significant regardless of the extent to
which the bone marrow was reconstituted with donor-derived
cells, even at low donor:competitor ratios (not shown), indicating
that expansion was not secondary to the lymphopenia or
thrombocytopenia that result from Runx1 deficiency [15,16].
Because the deletion was performed in the context of a bone
marrow chimera, the expansion was not caused by deletion in the
bone marrow niche, nor from enhanced engraftment. We
conclude that Runx1 has a specific, cell autonomous role in
regulating homeostatic LSK cell numbers.
Effects of Runx1 loss on LT-HSCs
Since LSK expansion was not affected by the extent of
chimerism, we switched to a simpler deletion strategy for many
of the subsequent experiments, using Vav1-Cre. Vav1-Cre
deletion, which is restricted to blood cells, initiates at 11.5 days
post coitus (dpc) in the fetus, and is approximately ,95% efficient
by 13.5 dpc in fetal liver cells [14,21]. We examined the
phenotypic and functional consequences of Runx1 loss in two
different LT-HSC populations in Runx1
f/f;Vav1-Cre mice; from the
14.5 dpc fetal liver, and from the bone marrow of young (6–8 week
old) adults. The percentage of phenotypic LT-HSCs in the 14.5
dpc fetal liver, as determined using SLAM markers [26], was 1.4
fold higher in Runx1
f/f;Vav1-Cre fetuses than in Runx1
f/f fetuses
(Figure 2A). However, a competitive limit dilution transplant
demonstrated that Runx1
f/f;Vav1-Cre fetal livers had 4-fold fewer
HSCs when the percentage of total donor-derived cells in
peripheral blood was assessed, suggesting that LT-HSCs were
functionally impaired (Figure 2B). We examined several potential
underlying causes of the moderately impaired engraftment. All
14.5 dpc fetal liver HSCs capable of engraftment are in the G1
phase of the cell cycle [27], so we determined whether Runx1
deficient HSCs had fewer cells in G1 by Pyronin Y/Hoechst
staining. We found, on the contrary, that Runx1
f/f;Vav1-Cre fetal
livers had significantly more CD48
- CD150
+ LSK cells in G1 as
compared to Runx1
f/f mice (Figure 3A). Since essentially all fetal
liver LT-HSCs are proliferating [27] the accumulation of cells in
G1 reflects a delay in cell cycle progression, consistent with many
previous reports that Runx1 promotes the G1 to S transition
(reviewed in [28,29,30,31,32,33]). Although one might predict that
an HSC population with a greater proportion of G1 phase cells
would provide superior engraftment, their lower proliferation rate
might confer a competitive disadvantage. Jacob et al. [18] reported
that chemokine receptor 4 (CXCR4) levels were decreased on
adult Runx1 deficient LSK cells, and homing of carboxyfluor-
escein succinimidyl ester (CFSE)-labeled total bone marrow was
lower. We also observed decreased levels of CXCR4 on Runx1
Table 1. Primers for qRT-PCR.
Gene Forward Primer Reverse Primer Taqman probe
Cd34 AGGCTCTGGAACTCCACACACTTT TAA GCA TAT GGC TCG GTG GGT GAT
Cd48 TGAGAGTGCTGCGTGAAACTGAGA ATGCTGGTCCTTTACCTCACACGA
Cd48 ATCGTGTGAGGTAAAGGACCAGCA AGGATTGCTGACTTG GCAGGTGTA
Gadph CATGGCCTTCCGTGTTCCTA TGTCATCATACTTGGCAGGTTTCT CCCAATGTGTCCGTCGTGGATCTGA
Hprt CTCCTCAGACCGCTTTTTGC TAACCTGGTTCATCATCGCTAATC
Mpl TATTGGCAGCAGCCCTGAA TGG ATG GTG TTG AGG ATG GAT A
Ndn CGTCCAGCAGAATTACCTGAAGT CATGATCTGCATCTTGGTGATTTC CCAGCGTGTGCCCCACATCG
Nov GAAGCATATTGGTTGAGGCAAAT GTGGGACAACTTCATTATGTTTCCT TTGCTGCGGCATGGCCCA
Prdm16 TCATCCCAGGAGAGCTGCATCAAA ATCACAGGAACACGCTACACGGAT
Slamf1 AAACCCAGGAGAACGAGAATG GGA GTT GCT TGC GGT GCA GTT GTA GAT
Tp53 AAAGGATGCCCATGCTACAGAGGA AGTAGACTGGCCCTTCTTGGTCTT
doi:10.1371/journal.pone.0028430.t001
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phenotypic MPP population (CD48
+ CD150
- LSK), and was not
apparent on LT-HSCs or ST-HSCs (Figure 3B,C). No differences
in the percentage of early apoptotic (7AAD
- Annexin V
+) HSC
populations were observed (not shown).
Adult Runx1
f/f;Vav1-Cre bone marrow had a very different cell
surface phenotype, i.e. a severe depletion of CD48
- CD150
+ LSK
cells (Figure 4A), similar to what was reported by Schindler et al.
[20] when they deleted Runx1 using Mx1-Cre. The depletion of
CD48
- CD150
+ LSK cells was pronounced by postnatal week 1
(not shown), and therefore did not correlate with the transition
from the fetal to adult HSC phenotype that takes place between 3
and 4 weeks after birth [34]. The percentage of CD48
- CD150
+
LSK cells in the fetal liver did not change in Runx1
f/f;Vav1-Cre mice
Figure 1. Runx1 deletion expands the phenotypic hematopoietic stem/progenitor pool in a cell-autonomous manner. A. Schematic
diagram of the experimental strategy. Mice stably engrafted with donor and competitor cells were injected with pIpC, and sacrificed for analyses. B.
Representative FACS analysis of lineage depleted donor-derived bone marrow LSK cells and Flt3
- and Flt3
+ fractions thereof 5 weeks post pIpC
injection. C. Donor chimerism within the Lin
- fraction of recipient marrow. Upon deletion of Runx1 (:/:), there was no change in the percent donor
contribution to the Lin
- fraction of cells (left panel), but within the donor-derived Lin
- fraction there was a significant increase in the percentage of
Sca1
+c-Kit
+ cells (right panel). Dots show the distribution of donor chimerism, the horizontal lines reflect the mean (695% CI). In animals whose bone
marrow contained ,30% Runx1-deficient Lin
- cells the difference was also significant (P,0.0001, not shown). D. Contribution of enriched donor LT-
HSC/ST-HSCs (LSK Flt3
-) and MPP/LMPPs (LSK Flt3
+) to recipient bone marrow (mean 6 95% CI). Left panel shows percent contribution, f/f n=10,
:/: n=12. Right panel shows total numbers, f/f n=14, :/: n=18.
doi:10.1371/journal.pone.0028430.g001
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phenotypic LT-HSCs was only apparent in the bone marrow.
However, the overall increase in mean fluorescence intensity of
CD48 on bone marrow LSK cells (Figure 4A) prompted us to
examine the expression of commonly used LT-HSC markers on
Runx1 deficient cells. The level of CD34 mRNA was lower in
Runx1 deficient LSKF
- cells (Figure 4B), and the mean
fluorescence intensity of cell surface CD34 was moderately
decreased (Figure 4C). CD48 mRNA levels were not significantly
changed (Figure 4B), but cell surface CD48 was markedly elevated
on LSKF
- (17.3 fold), and on LSKF
+ cells (6.4 fold) (Figure 4C).
CD150 levels were also elevated on Runx1 deficient LSKF
- (3 fold)
and LSKF
+ cells (14.1 fold), despite the fact that CD150 mRNA
levels were decreased (Figure 4B,C). Co-staining for all four
markers revealed that the phenotypic LT-HSC population defined
using CD34 and Flt3 (and LSK cells in general) was shifted
upwards on the CD48 axis, and as a result the majority of CD34
-
Flt3
- LSK cells did not fall within the CD48
- gate (Figure 4D).
Thus several commonly used LT-HSC markers are dysregulated
on Runx1 deficient HSCs, and may be unreliable for the definition
of phenotypic HSCs in the adult bone marrow.
We used CD34 in combination with Flt3 to re-examine the
composition of LSK cells in the bone marrow of 6–8 week old
Runx1
f/f;Vav1-Cre mice. In contrast to the marked decrease in
phenotypic LT-HSCs observed using SLAM markers, we found a
2 fold increase in the percentage of CD34
- Flt3
- LSK cells, and an
increase in phenotypic ST-HSCs (CD34
+ Flt3
- LSK), as shown
previously [18] (Figure 4E). The percentage of Flt3
+ LSK cells was
lower, in contrast to what was observed upon deletion with Mx1-
Cre (Figure 1B).
We used limit dilution transplants to determine which, if any,
phenotypic markers correlated with functional outcome. Since
Runx1 deletion impairs lymphoid development, while it moder-
ately expands LSK cells and myeloid progenitors in the bone
marrow [15,16], we assessed contribution in several ways. The
frequency of LT-HSCs was 3.6 fold lower in young adult (6–8
week old) Runx1
f/f;Vav1-Cre mice, similar to what we observed in
the fetal liver, when donor contribution to total nucleated
Figure 2. Effect of Runx1 deletion on fetal HSCs. A. The percentage of phenotypic Runx1 deficient fetal liver HSCs (14.5 dpc) defined using
SLAM markers. Runx1 was deleted in fetal HSCs using Vav1-Cre. The number of fetal liver cells was equivalent. Plots indicate the percentage of CD48
-
CD150
+ LSK cells in the fetal liver; error bars represent 95% CI. Data are compiled from 7 Runx1
f/f (f/f) and 6 Runx1
f/f; Vav1-Cre fetuses (D/D) in two
experiments. B. Competitive limit dilution transplant. Dilutions of 14.5 dpc fetal liver cells (Ly5.2
+) were injected along with 2610
5 Ly5.1
+ adult bone
marrow cells into irradiated Ly5.1/5.2 recipients. The contribution of Ly5.2
+ cells to peripheral blood was assessed, and recipients with $5% donor-
derived cells at $16 weeks were deemed reconstituted. Data are compiled from three different experiments with a total of 6 to 13 mice per data
point. The frequency of LT-HSCs in the wild type fetal was 1 in 17,184 (95% CI range = 1 in 22,355 to 1 in 13,208). The frequency of LT-HSCs in the
Runx1
f/f;Vav1-Cre fetal liver was 1 in 68,413 (range = 1 in 93,523 to 1 in 50,045).
doi:10.1371/journal.pone.0028430.g002
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contribution to myeloid lineage (Mac1
+) cells in peripheral blood
was scored, there was a fairly comparable (2.7 fold) decrease in
LT-HSC frequency. However, there was no difference in the
frequency of Runx1
f/f;Vav1-Cre versus Runx1
f/f LT-HSCs when
contribution to whole bone marrow, bone marrow Mac1
+ cells, or
LSK cells were scored (Figure 4F and Table 2). These
discrepancies are caused by differences in the contribution of
Runx1
f/f;Vav1-Cre cells to various hematopoietic populations.
Calculation of repopulating units (RU) based on contribution to
cells in bone marrow or peripheral blood showed that Runx1
f/f LT-
HSCs contributed equivalently to total nucleated peripheral blood
cells, Mac1
+ peripheral blood cells, total bone marrow, Mac1
+
bone marrow cells, and LSK cells (Figure 4G). Runx1
f/f;Vav1-Cre
LT-HSCs, on the other hand, contributed unevenly to these
populations, with the most dramatic difference in the contribution
to total peripheral blood (calculated as 0.3 RU) versus bone
marrow LSK cells (10.6 RU). Thus, using a fairly typical cutoff of
$1% donor derived cells, a small number of recipients scored
positive based on contribution to one lineage and negative based
on contribution to another. In summary, it appears that the
number of phenotypic and functional LT-HSCs in Runx1
f/f;Vav1-
Cre mice varies depending on the markers used, and the criteria
used to count them. This may explain why independent
Figure 3. Proliferation profile and CXCR4 expression on Runx1 deficient fetal liver HSCs. A. Cell cycle analysis of sorted CD48
-CD150
+ LSK
cells stained with Hoechst and analyzed by FACS. Error bars represent 95% CI. Differences between f/f and :/: cells in G0/G1 and M/G2 were significant
(asterisks, P=0.003 and 0.004, respectively). n=6. B. Representative scatter plots for analysis of LSK and phenotypic LT-HSC, ST-HSC, and MPP
populations are shown on left, and histograms for CXCR4 levels on the right. CD48
- CD150
- LSK cells are labeled ST-HSC based on analysis by Foudi et
al. in adult marrow [67]. C. Analysis of CXCR4 levels on Runx1 deficient fetal liver HSCs. The mean fluorescence intensity (MFI) of CXCR4 is plotted for
LSK, phenotypic LT-HSC (CD48
-CD150
+ LSK), ST-HSC (CD48
-CD150
- LSK), and MPP (CD48
+CD150
- LSK) populations (n=5 or 6 fetuses, error bars
represent 95% CI). Significance was determined by unpaired, two-tailed Student’s t-test.
doi:10.1371/journal.pone.0028430.g003
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consequences of Runx1 deletion in the LT-HSC population.
Incorporating all of our findings we conclude that there is a
moderate, 2–4 fold decrease in the number of Runx1 deficient LT-
HSCs in young adult bone marrow if contribution to peripheral
blood is assessed, and no difference if contribution to bone marrow
is scored. No markers accurately predicted the difference in LT-
HSC frequencies in Runx1
f/f versus Runx1
f/f;Vav1-Cre bone
marrow. The markers that best approximated functional activity
in bone marrow LT-HSCs were CD34
- Flt3
- LSK, and these were
used in all subsequent analyses.
Runx1 loss slows HSC proliferation and reduces
apoptosis
We examined various phenotypic parameters of Runx1
deficient HSCs to gain insights into the pre-leukemic state. BrdU
labeling revealed that the Runx1 deficient LT-HSCs, ST-HSCs,
and MPPs in the adult bone marrow cycled more slowly than their
wild type counterparts, with more cells remaining in G0/G1
(Figure 5A,B). There were fewer quiescent CD34
- Flt3
- LSK cells
in the Runx1
f/f;Vav1-Cre marrow (Figure 5C,D), whereas quies-
cence in the ST-HSC population (CD34
+ Flt3
- LSK) was not
altered. Thus subtle alterations in cell cycle properties result in
somewhat more LT-HSCs exiting quiescence, but all LSK cells
progressing more slowly through cell cycle and accumulating in
G1. There were fewer Annexin V
+ CD34
- Flt3
- LSK and CD34
+
Flt3
- LSK cells (Figure 5E), suggesting that Runx1 positively
regulates apoptosis in HSCs, as noted previously [17]. Thus LSK
expansion may be caused by a decreased rate of apoptosis, but not
by increased proliferation.
We examined the effect of Runx1 deficiency on the response to
myelotoxic stress. There was no difference in the survival of
Runx1
f/f and Runx1
f/f;Vav1-Cre mice following weekly injections
with 5-fluorouracil (5-FU), which kills cycling cells (Figure 6A).
Immature c-Kit
+ cells in the peripheral blood of Runx1
f/f;Vav1-Cre
mice were elevated before 5-FU treatment, and after the second 5-
FU injection (Figure 6A). The percentage of Runx1
f/f;Vav1-Cre LS
cells in the bone marrow (cell surface c-Kit in bone marrow is
decreased by 5-FU and could not be used as a marker [35]) was 5-
fold higher than that of Runx1
f/f LS cells following two rounds of 5-
FU injections (Figure 6A). Therefore Runx1 deficiency does not
sensitize mice or HSCs/progenitors to myelotoxic stress.
We also examined the effect of forced proliferation of LT-HSCs
through serial transplantation. Since the frequency of Runx1
deficient LT-HSCs in the bone marrow is either unaltered or
lower by approximately 3–4 fold (Table 2), we transplanted
primary recipients with two different doses of Runx1
f/f;Vav1-Cre
bone marrow cells, either equal to the number of control Runx1
f/f
cells (1610
6), or four fold more (4610
6), all without competitors.
Bone marrow from each primary recipient (2610
6 cells) was then
serially transplanted three times, and donor contribution to Mac1
+
peripheral blood cells assessed (Figure 6B). When an initial dose of
1610
6 bone marrow cells was used, no recipients of Runx1
f/f;Vav1-
Cre cells were engrafted in the fourth round, compared to 19% of
mice transplanted with Runx1
f/f cells. However, the fraction of
reconstituted 3
0 and 4
0 recipients was the same when starting
Figure 4. LT-HSC marker expression is altered on Runx1 deficient HSCs. A. Percentage of adult bone marrow LSK cells expressing SLAM
markers. The gates were drawn based on fluorescence-minus-one controls using Runx1
f/f (f/f) and Runx1
f/f;Vav1-Cre (D/D) cells. The bar graph on the
right represents the percentage of CD48
- CD150
+ LSK cells in total bone marrow, averaged from 6-7 mice. Error bars indicate SEM. B. Real time PCR for
mRNA encoding LT-HSC markers in donor derived LSKF
- cells sorted from recipients of Runx1
f/f and Runx1
f/f; Mx1-Cre bone marrow. n=4–6 mice of
each genotype. Error bars represent SEM. See Figure 1B for gating strategy. C. Mean fluorescence intensity of CD34, CD48, and CD150 on LSKF
- and
LSKF
+ cells (n=6; error bars = SEM. D. Simultaneous analysis of all four LT-HSC markers on Runx1
f/f and Runx1
f/f;Vav1-Cre LSK cells. The LSK
population (blue) and CD34
- Flt3
- LSK population (red) in the middle plots are analyzed for CD48 and CD150 expression in the right hand plots. Note
the upward shift in CD48 levels, and rightward shift of C150 on Runx1 deficient HSCs. E. The percentage of phenotypic LT-HSCs and ST-HSCs in the
bone marrow of 6-8 week old Runx1
f/f and Runx1
f/f; Vav1-Cre mice determined using CD34 and Flt3 markers. Data are averaged from 6 mice, error bars
indicate 95% CI. F. Competitive limit dilution transplant. Bone marrow from 6-8 week old Runx1
f/f or Runx1
f/f;Vav1-Cre mice was injected along with
2610
5 Ly5.1
+ adult bone marrow cells into irradiated Ly5.1/5.2 recipients. Contribution of Ly5.2
+ cells to peripheral blood (top graph) and bone
marrow LSK cells (bottom graph) were assessed. Recipients with $1% donor-derived cells at $16 weeks were deemed reconstituted. Data are
compiled from three different experiments with a total of 5 to 13 mice per data point. G. Repopulating units (RU) determined by contribution to
different blood cell populations. Competitor cells (2610
5, Ly5.1) were transplanted with either 1610
5 Runx1
f/f or 3610
5 Runx1
f/f; Vav1-Cre bone
marrow cells. RUs were calculated according to Harrison et al. [68].
doi:10.1371/journal.pone.0028430.g004
Table 2. LT-HSC frequencies in adult bone marrow determined by contribution to different lineages.
Genotype Donor contribution Frequency
Upper range
(95% CI)
Lower range
(95% CI)
Relative frequency
compared to Runx1
f/f P value
Runx1
f/f PB (nucleated cells) 1:19,299 1:11,607 1:32,088
Runx1
f/f PB Mac1
+ cells 1:21,992 1:12,661 1:38,202
Runx1
f/f BM (nucleated cells) 1:26,288 1:15,266 1:45,268
Runx1
f/f BM Mac1
+ cells 1:24,095 1:13,877 1:41,838
Runx1
f/f BM LSK cells 1:37,769 1:21,018 1:67,869
Runx1
f/f;Vav1-Cre PB (nucleated cells) 1:69,965 1:39,351 1:12,4396 0.28 0.001
Runx1
f/f;Vav1-Cre PB Mac1
+ cells 1:58,961 1:33,389 1:104,120 0.37 0.01
Runx1
f/f;Vav1-Cre BM (nucleated cells) 1:26,120 1:15,579 1:43,791 0.20 0.49
Runx1
f/f;Vav1-Cre BM Mac1
+ cells 1:26,118 1:15,581 1:43,783 1.71 0.42
Runx1
f/f;Vav1-Cre BM LSK cells 1:28,833 1:17,089 1:48,649 1.47 0.25
doi:10.1371/journal.pone.0028430.t002
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PLoS ONE | www.plosone.org 8 December 2011 | Volume 6 | Issue 12 | e28430Figure 5. Alterations in cell cycle and apoptosis in Runx1 deficient adult HSCs. A. Representative scatter plots for BrdU cell cycle analysis.
Mice were exposed to BrdU for three days prior to analysis. CD34
- Flt3
- LSK and CD34
+ Flt3
- LSK cells were analyzed for BrdU and DNA content in plots
on the right. B. Summary of data from a total of 9 Runx1
f/f and Runx1
f/f;Vav1-Cre mice. Error bars indicate 95% CI. P values for differences between wild
type and mutant cells in G0/G1 are indicated in the bars. C. Runx1
f/f and Runx1
f/f;Vav1-Cre CD34
- Flt3
- LSK cells were sorted from bone marrow by
multicolor FACS, stained with Hoechst 33342 and Pyronin Y, and analyzed by flow cytometry. Scatter plots show representative cell cycle
distributions. D. Summary of quiescence analysis (n=6 to 8). Error bars represent 95% CI. E. Annexin V staining of Runx1
f/f and Runx1
f/f;Vav1-Cre CD34
-
Flt3
- LSK and CD34
+ Flt3
- LSK bone marrow cells (5-7 mice). Error bars represent SEM.
doi:10.1371/journal.pone.0028430.g005
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6 Runx1
f/f and 4610
6 Runx1
f/f;Vav1-Cre bone marrow
cells, which contain almost equivalent numbers of LT-HSCs, were
transplanted (Figure 6C). Therefore, although the frequency of
LT-HSCs was 3-4 fold lower in the original Runx1
f/f;Vav1-Cre bone
marrow, the LT-HSCs were normal with respect to the efficiency
with which they engrafted and expanded in the subsequent
transplant recipients, and in their self-renewal. Consistent with the
similar engraftment efficiency, there was no significant difference
in the ability of CFSE-labeled CD34
- Flt3
- LSK cells from Runx1
f/
f;Vav1-Cre mice to home to the bone marrow (Figure 6C).
Genes and proteins dysregulated in Runx1 deficient HSCs
We examined changes in the global gene expression profiles to
gain insights into the molecular mechanisms by which Runx1 loss
creates preleukemic HSCs. Bone marrow chimeras stably
reconstituted by donor Runx1
+/+; Mx1-Cre
+/+ or Runx1
f/f; Mx1-
Cre marrow were injected with pIpC to induce Cre, and donor-
derived LSK, LSKF
-, and LSKF
+ cells from individual recipients
purified by cell sorting. Total RNA was harvested from each
sample and analyzed using Affymetrix Mouse Genome 430 2.0
GeneChip arrays. Using a significance threshold of 0.005, we
identified 902 unique genes that were differentially expressed $
1.5 fold between Runx1
+/+ and Runx1-deficient (Runx1
D/D) LSK
cells (Table S1), 2147 differentially expressed genes in LSKF
- cells
(Figure 7A and Table S2), and 1789 genes in LSKF
+ cells
(Figure 7A and Table S3). Some of the most highly under-
expressed genes in LSKF
- cells included Nov, Mpl, and Prdm16, all
of which encode positive regulators of HSC self-renewal or
engraftment (Figure 7B) [36,37,38,39]. One of the most highly
under-expressed genes was Ndn, which was previously implicated
in regulating HSC quiescence [40], although later studies found no
role for Ndn in maintaining steady state hematopoiesis or
protecting against stem cell exhaustion [41]. Many genes
implicated in controlling HSC quiescence, or the distribution
between G0/G1 and S/G2/M, including Gfi1, Pten, Foxo family
genes, Elf4, Cdkn2c, Hoxb4, Myc, Mll1, Junb, Cdkn2a, and Tp53
[40,42,43] were not affected by Runx1 deficiency, although Gene
Set Enrichment Analysis (GSEA) identified both the cell cycle and
p53 pathways as being significantly dysregulated (Figure 7C). Of
the 2147 and 1789 genes whose expression was dysregulated in
either or LSKF
- or LSKF
+ cells, respectively, 664 contained a
consensus site that was occupied by Runx1 in a human
Figure 6. Runx1 deficient HSCs are not exhausted by proliferative stress. A. Kaplan-Meier survival curve of mice following weekly injections
of 5-FU (on days 1, 7, 14) is on the left. Runx1
f/f, n=10; Runx1
f/f;Vav1-Cre, n=9. The middle graph represents the percentage of c-Kit
+ cells in peripheral
blood before 5-FU injection (d0), and various days following weekly injection (6-12 mice per data point). Error bars are SEM. Right hand graph is
percentage of LS cells in the bone marrow 7 days after the second 5-FU injection. Runx1
f/f,n=7 .Runx1
f/f;Vav1-Cre, n=8. B. Serial transplantation of
bone marrow cells. Numbers above bars indicate the number of transplant recipients, not including those that died within two weeks from radiation
toxicity. The genotypes and doses represent the bone marrow cells used to engraft primary recipients. 2610
6 cells from primary recipients were
transplanted into secondary recipients, and the process was repeated twice more. C. Homing assay. CD34
- Flt3
- LSK cells were isolated by FACS,
labeled with CFSE, and 1000 cells transplanted into 4-5 recipients along with 2 x10
5 unlabeled carrier cells. Bone marrow cells (.10
7) were analyzed
16 hours later by FACS. Shown is the percentage of live CFSE
+ Ter119
- cells. Data are representative of two experiments.
doi:10.1371/journal.pone.0028430.g006
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PLoS ONE | www.plosone.org 10 December 2011 | Volume 6 | Issue 12 | e28430Figure 7. Microarray analysis of genes mis-expressed in Runx1 deficient HSCs. A. Heat plot of 4707 probe sets, representing 3820 genes,
differentially expressed between LSKF
- and LSKF
+ cells isolated from mice transplanted with Runx1
f/f and Runx1
f/f; Mx1-Cre bone marrow, with a
significance threshold of P=0.005. Each column shows gene expression from donor cells from an independent transplant recipient. Red, . than the
average, blue, , than the average. B. Quantitative real-time PCR (qRT-PCR) performed on several genes to independently validate the microarray
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thus the majority are likely to be indirect Runx1 targets. We note,
though, that the gene expression analysis may be compromised by
alterations in the expression of markers used to isolate the
populations in question.
Discussion
We examined the cell-intrinsic properties of Runx1 deficient
HSCs using both phenotypic and functional assays. One of our
goals was to attempt to reconcile the contradictory reports in the
literature regarding the effects of Runx1 loss on phenotypic and
functional HSCs. We discovered that one of the inherent difficulties
in studying Runx1 deficient HSCs, which may have contributed to
some of the discrepancies in the literature, is the uncertainty
regarding phenotypic markers. Specifically, we found that markers
commonly used to subdivide the LSK population (CD34/Flt3
versus CD48/CD150) yielded different phenotypic LT-HSC
frequencies. This may be caused, in part, by direct regulation by
Runx1 of genes encoding one or more of these markers, as has been
noted previously with other antigens commonly used to define
phenotypic blood cell populations in Runx1 deficient animals. The
most well known example of this is the derepression of CD4
expression on thymocytes. Cd4 contains an extensively character-
ized silencer element that is regulated by Runx1, and deletion of
either Runx1 or the silencer causes inappropriate CD4 expression
in double negative (CD4
- CD8
-) thymocytes [45]. A recent ChIP-
Seq analysis of the HPC-7 hematopoietic progenitor cell line
showed that all but one gene encoding commonly used HSC
markers (Kit, Flt3, Cd34, Cd48, Slamf1/CD150) were occupied by
Runx1 and thus are direct Runx1 targets [44]. However not all
marker genes occupied by Runx1 appear to be regulatedat the level
of mRNA production or stability. Cd48 mRNA, for example, is
present in normal amounts, but cell surface CD48 is strikingly
elevated on Runx1 deficient LSK cells. The mechanistic basis for
CD48 dysregulation is unclear. One possibility is that Runx1
indirectly regulates CD48 translation through a microRNA.
However, TargetScan identified no microRNA target sites in the
Cd48 39UTR, and while PicTar identified a site for mmu-miR-31,
the expression of mmu-miR-31 is upregulated rather than
downregulated in Runx1 deficient HSCs (not shown). The
pronounced elevation of cell surface CD48 levels is the first
example of a dysregulated SLAM marker of which we’re aware.
Runx1 deficiency blocks lymphocyte development, while at the
same time expands LSK cells and granulocyte progenitors in the
bone marrow [14,15,16,17,18]. These features complicate the
evaluation of functional LT-HSCs, the methods for which generally
employ a cutoff value for positive engraftment. Thus, we obtained
slightly different LT-HSC frequencies depending on the lineage we
assessed. LT-HSC frequencies were 3–4 fold lower in Runx1
f/f;Vav1-
Cre bone marrow when contribution to peripheral blood was scored,
but not significantly different from those in Runx1
f/f mice when
contribution to bone marrow was assessed. The difference in LT-
HSC frequencies calculated from the peripheral blood and bone
marrow could be caused by impaired output of Runx1 deficient
HSCs to differentiated progeny in the peripheral blood, from
selective expansion of HSCs and progenitors in the bone marrow, or
both. Ichikawa et al. [16] previously reported that LT-HSC
frequencies were elevated 10 fold when Runx1 was deleted in all
bone marrow cells with Mx1-Cre, which they assessed by PCR
analysis for Y-chromosome positive donor-derived cells in the bone
marrow of female recipients. Although we observed no difference in
thefrequencyofwildtypeand Runx1deficientHSCswhen assessing
bone marrow engraftment, the two experiments are difficult to
compare since they used different deletion strategies, and the
sensitivity and selectivity of the techniques used to score engraftment
were also dissimilar. Jacob et al. [18], on the other hand, reported a
2.7 fold decrease in the frequency of LT-HSCs between aged (40
week old) Runx1
f/f;Mx1-Cre mice and Runx1
f/f mice, and concluded
that Runx1 deficiency caused an age-dependent HSC exhaustion.
However, Jacob et al. [18] did not compare the frequency of
functional LT-HSCs in young adult mice. Since we observed similar
decreases in LT-HSC frequencies in the fetal liver (4.0 fold) and in
youngadultbonemarrow(3.6fold)whenweassessedcontributionto
peripheralblood,we do notthinkthe2.7decreaseobservedbyJacob
etal.inold miceisduetoexhaustion.Thisinterpretationissupported
by 5-FU and serial transplant experiments, which uncovered no
disadvantage conferred by Runx1 deficiency.
Biallelic or monoallelic mutations in RUNX1 are found in
myeloid malignancies, and in many cases are thought to be
initiating mutations that generate a pre-leukemic HSC. We
endeavored to define the properties of Runx1 deficient HSCs
that contribute to this pre-leukemic state. A potent pre-leukemic
HSC should be retained in the bone marrow for many years,
clonally expand, and exhibit an elevated level of genetic or
epigenetic instability. Runx1 deficient HSCs have properties
consistent with at least two of these features. First, and most
importantly, Runx1 deficient HSCs do not undergo exhaustion
and therefore perdure. We note that loss of function mutations
that negatively impact HSC engraftment or activity (Pten, Gfi1,
Foxo1,3,4, Bmi1, Moz, Mll1) [46,47,48,49,50,51,52,53,54] are
either uncommon or not observed in AML, perhaps because
HSCs that acquire these mutations as a first hit have a competitive
disadvantage in the bone marrow or are rapidly lost.
The perdurance of Runx1 deficient HSCs may be conferred, in
part, by their slow cycling behavior. Runx1 deficient HSCs
contain a significantly higher percentage of cells in G1, thus Runx1
normally functions to promote cell cycle progression. This is an
evolutionarily conserved property of Runx1 in stem cell popula-
tions. For example, the C. elegans homologue RNT-1 promotes the
proliferation of lateral hypodermic stem cells (seam cells), and sea
urchin Runx (SpRunt-1) is necessary for the proliferation of late
stage blastula cells [55,56]. In mammals, Runx1 sustains
proliferation and prevents the differentiation of transient ampli-
fying progenitors and precursors of olfactory sensory neurons, and
promotes proliferation of hair follicle stem cells and keratinocytes
[57,58]. However Runx1 can also repress proliferation. For
example, overexpression of Runx1 in hematopoietic progenitors
cultured in vitro increased the proportion of cells in G1 [59], and
ectopic expression of Runx1 in primary mouse and human
fibroblasts induced a senescence-like growth arrest with an
accumulation of cells in G1 [60,61,62]. Whether Runx1 promotes
or represses proliferation appears to be cell context dependent,
data. Data shown are the mean fold change in expression (6 SEM), normalized to Gapdh expression, between Runx1
D/D (n=3) and Runx1
f/f (n=3)
LSKF
- samples. C. GSEA profiles illustrating the correlation between genes negatively regulated by Runx1 in LSK cells, and genes sets of cell cycle and
p53 pathways. Enrichment score, p values and FDR q-values are shown under the enrichment plots. Number of permutations was set to 1000. D.
Venn diagram illustrating overlap between dysregulated genes in Runx1 deficient LSKF
- and LSKF
+ cells, and genes occupied by Runx1 in the HPC-7
line [44]. For list of genes see Table S4.
doi:10.1371/journal.pone.0028430.g007
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understood.
The slow replication of Runx1 deficient HSCs could protect
them from genotoxic stress, leading to selective expansion. It has
long been known that cultured cells in early G1 are relatively
radioresistant [63,64]. It was recently shown that inducing a
pharmacological G1 arrest in HSCs and progenitors mitigated
hematological toxicity and mortality following total body irradi-
ation [65]. Delays in cell cycle progression in hematopoietic stem
and progenitor cells are not unique to Runx1 loss, and were also
observed in cells expressing the dominant inhibitors AML1-ETO
and CBFß-SMMHC [28,29,31,66]. The defective differentiation
of Runx1 deficient cells along the lymphoid and megakaryocytic
pathways would, of course, contribute to the clinical features of the
full-blown disease, such as the multilineage dysplasia in MDS, or
the poorly differentiated blast cells in AML.
In summary, we have attempted to resolve controversies in the
literature regarding the effect of Runx1 loss on both phenotypic
and functional HSCs. We conclude that the negative impact of
Runx1 loss on the frequency and self-renewal of functional LT-
HSCs is only modest or absent. Runx1 deficient HSCs replicate
slowly and persist in the bone marrow, providing a pool of
preleukemic HSCs poised to acquire secondary mutations that
would promote their growth and progression to MDS or AML.
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Table S1 Gene expression changes in LSK cells. Listed
are changes .1.5 fold, with a significance threshold of 0.005. The
data correspond to 1026 probesets and 902 unique genes.
(XLS)
Table S2 Gene expression changes in LSKF
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